A retrospective study comparing the adherence rates between formulations of Deferasirox, a dispersible tablet for oral suspension (DT) versus A new film-coated tablet formulation (FCT) among patients with sickle cell disease and β-thalassemia
Latest Information Update: 15 Dec 2021
At a glance
- Drugs Deferasirox (Primary) ; Deferasirox
- Indications Iron overload
- Focus Therapeutic Use
- 15 Dec 2021 New trial record